Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions.
HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on customer response.
It marks Loughborough, England-based Nemaura’s first partnership deal in the U.S.
Get the full story at our sister site, Drug Delivery Business News.